WithdrawnNot Applicable

Identification of Genomic Biomarkers for Rheumatoid Arthritis With Late Onset

Stopped: No funding

0Started 2025-05-28

Plain-language summary

Rheumatoid arthritis (RA) is a disabling disease leading to joint and bones destruction. This autoimmune disease is multifactorial, and some genetic and environmental risk factors are already described. However, a part of heritability is still unknown. Previous genomics studies dedicated to deciphering this missing heritability did not pay attention to age of onset. The purpose of this protocol is to determine genomic markers which are specific of RA with an age of onset above 65 years old. Indeed, clinical presentation, treatment tolerance and efficiency, and frequent comorbidities of this phenotype are particular. This signature of genomic biomarkers will be integrated in known molecular pathways to highlight specificities, helpful for biological targets identification.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patient with RA diagnosed before 60 years (PRp group) * patient with RA diagnosed from 65 years (PRt group) * patient without RA followed for osteoarthritis matched with patient of PRt according to age (+/- 1 year) and sex (Tem group). * relative of patient PRt, without RA or with RA, regardless of age of onset (Ap group) * patient who agreed to participate in the study and signed an informed consent Exclusion Criteria: * other inflammatory and/or autoimmune known disease for patients of PRp and PRt groups * first symptoms of osteoarthritis before 40 years, other known inflammatory disease, other known autoimmune disease for Tem group.

What they're measuring

Genomic signature for late onset rheumatoid arthritis

Timeframe: at day 0

Gene expression for late onset rheumatoid arthritis

Timeframe: at day 0

Trial details

NCT IDNCT05808309

SponsorCentre Hospitalier Sud Francilien

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-01-01